JPS63277672A - 置換された１，３‐ジオキソランおよび１，３‐ジオキサン誘導体、その製法と使用 - Google Patents
置換された１，３‐ジオキソランおよび１，３‐ジオキサン誘導体、その製法と使用Info
- Publication number
- JPS63277672A JPS63277672A JP63081182A JP8118288A JPS63277672A JP S63277672 A JPS63277672 A JP S63277672A JP 63081182 A JP63081182 A JP 63081182A JP 8118288 A JP8118288 A JP 8118288A JP S63277672 A JPS63277672 A JP S63277672A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- tolyl
- dioxolane
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical class C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 title description 5
- 150000000093 1,3-dioxanes Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 54
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 239000003472 antidiabetic agent Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229940125708 antidiabetic agent Drugs 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- -1 polyoxyethylene stearate Polymers 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- KONLOUNOGLJAIE-UHFFFAOYSA-N 2-tert-butyl-2-(4-methylphenyl)-1,3-dioxolane Chemical compound C1=CC(C)=CC=C1C1(C(C)(C)C)OCCO1 KONLOUNOGLJAIE-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 230000003178 anti-diabetic effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000002431 hydrogen Chemical group 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229960004580 glibenclamide Drugs 0.000 description 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JFSURDQTNPEVAL-UHFFFAOYSA-N 2-(1-methylcyclohexyl)-2-(4-methylphenyl)-1,3-dioxolane Chemical compound C1=CC(C)=CC=C1C1(C2(C)CCCCC2)OCCO1 JFSURDQTNPEVAL-UHFFFAOYSA-N 0.000 description 2
- KMLAMOMPQVOCBA-UHFFFAOYSA-N 2-(1-methylcyclopropyl)-2-(4-methylphenyl)-1,3-dioxolane Chemical compound C1=CC(C)=CC=C1C1(C2(C)CC2)OCCO1 KMLAMOMPQVOCBA-UHFFFAOYSA-N 0.000 description 2
- ZRYUJKCBKVZXPJ-UHFFFAOYSA-N 2-(2-methylbutan-2-yl)-2-(4-methylphenyl)-1,3-dioxolane Chemical compound C=1C=C(C)C=CC=1C1(C(C)(C)CC)OCCO1 ZRYUJKCBKVZXPJ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FDSAYCYOKLMSHG-UHFFFAOYSA-N 2,2-dimethyl-1-(4-methylphenyl)pentan-1-one Chemical compound C1(=CC=C(C=C1)C(=O)C(CCC)(C)C)C FDSAYCYOKLMSHG-UHFFFAOYSA-N 0.000 description 1
- ZYWGAHRBGCEFAO-UHFFFAOYSA-N 2,2-dimethyl-1-(4-methylphenyl)propan-1-one Chemical compound CC1=CC=C(C(=O)C(C)(C)C)C=C1 ZYWGAHRBGCEFAO-UHFFFAOYSA-N 0.000 description 1
- LUFBGYMZEQHSPV-UHFFFAOYSA-N 2-(3-ethylpentan-3-yl)-2-(4-methylphenyl)-1,3-dioxolane Chemical compound C=1C=C(C)C=CC=1C1(C(CC)(CC)CC)OCCO1 LUFBGYMZEQHSPV-UHFFFAOYSA-N 0.000 description 1
- UWWGSXYTVPACKO-UHFFFAOYSA-N 2-tert-butyl-2-(3-methylphenyl)-1,3-dioxolane Chemical compound CC1=CC=CC(C2(OCCO2)C(C)(C)C)=C1 UWWGSXYTVPACKO-UHFFFAOYSA-N 0.000 description 1
- PUGWYZCAGAHQNO-UHFFFAOYSA-N 2-tert-butyl-2-(4-methylphenyl)-1,3-dioxane Chemical compound C1=CC(C)=CC=C1C1(C(C)(C)C)OCCCO1 PUGWYZCAGAHQNO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- ZWPWLKXZYNXATK-UHFFFAOYSA-N bis(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(C)C=C1 ZWPWLKXZYNXATK-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940125890 compound Ia Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000004563 wettable powder Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/12—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3411887A | 1987-04-01 | 1987-04-01 | |
| US034118 | 1987-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63277672A true JPS63277672A (ja) | 1988-11-15 |
Family
ID=21874422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63081182A Pending JPS63277672A (ja) | 1987-04-01 | 1988-03-31 | 置換された１，３‐ジオキソランおよび１，３‐ジオキサン誘導体、その製法と使用 |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS63277672A (pt) |
| KR (1) | KR880012224A (pt) |
| AU (1) | AU1400788A (pt) |
| BE (1) | BE1000783A3 (pt) |
| DE (1) | DE3810874A1 (pt) |
| DK (1) | DK179288A (pt) |
| ES (1) | ES2011831A6 (pt) |
| FR (1) | FR2613226B1 (pt) |
| GB (1) | GB2202849A (pt) |
| GR (1) | GR880100196A (pt) |
| HU (1) | HUT50156A (pt) |
| IL (1) | IL85920A0 (pt) |
| IT (1) | IT1219895B (pt) |
| LU (1) | LU87176A1 (pt) |
| NL (1) | NL8800805A (pt) |
| PT (1) | PT87127B (pt) |
| SE (1) | SE8801166L (pt) |
| ZA (1) | ZA882350B (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8701961D0 (en) * | 1987-01-29 | 1987-03-04 | Unilever Plc | Perfumery materials |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3235589A1 (de) * | 1982-09-25 | 1984-03-29 | Hoechst Ag, 6230 Frankfurt | Benzylether von phenol-mannich-basen, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen, zwischenprodukte und verfahren zu deren herstellung |
-
1988
- 1988-03-23 LU LU87176A patent/LU87176A1/fr unknown
- 1988-03-28 BE BE8800360A patent/BE1000783A3/fr not_active IP Right Cessation
- 1988-03-28 FR FR888804153A patent/FR2613226B1/fr not_active Expired
- 1988-03-29 GR GR880100196A patent/GR880100196A/el unknown
- 1988-03-29 SE SE8801166A patent/SE8801166L/xx not_active Application Discontinuation
- 1988-03-29 GB GB08807503A patent/GB2202849A/en not_active Withdrawn
- 1988-03-30 DK DK179288A patent/DK179288A/da not_active Application Discontinuation
- 1988-03-30 AU AU14007/88A patent/AU1400788A/en not_active Abandoned
- 1988-03-30 NL NL8800805A patent/NL8800805A/nl not_active Application Discontinuation
- 1988-03-30 IT IT47797/88A patent/IT1219895B/it active
- 1988-03-30 PT PT87127A patent/PT87127B/pt not_active IP Right Cessation
- 1988-03-30 DE DE3810874A patent/DE3810874A1/de not_active Withdrawn
- 1988-03-30 ES ES8801002A patent/ES2011831A6/es not_active Expired - Lifetime
- 1988-03-30 KR KR1019880003491A patent/KR880012224A/ko not_active Application Discontinuation
- 1988-03-30 HU HU881581A patent/HUT50156A/hu unknown
- 1988-03-30 IL IL85920A patent/IL85920A0/xx unknown
- 1988-03-31 ZA ZA882350A patent/ZA882350B/xx unknown
- 1988-03-31 JP JP63081182A patent/JPS63277672A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT87127A (pt) | 1988-04-01 |
| AU1400788A (en) | 1988-10-06 |
| DE3810874A1 (de) | 1988-10-20 |
| IT1219895B (it) | 1990-05-24 |
| NL8800805A (nl) | 1988-11-01 |
| SE8801166L (sv) | 1988-10-02 |
| IL85920A0 (en) | 1988-09-30 |
| GB2202849A (en) | 1988-10-05 |
| IT8847797A0 (it) | 1988-03-30 |
| ZA882350B (en) | 1989-12-27 |
| DK179288D0 (da) | 1988-03-30 |
| SE8801166D0 (sv) | 1988-03-29 |
| PT87127B (pt) | 1992-07-31 |
| GB8807503D0 (en) | 1988-05-05 |
| GR880100196A (el) | 1989-01-31 |
| KR880012224A (ko) | 1988-11-26 |
| HUT50156A (en) | 1989-12-28 |
| DK179288A (da) | 1988-10-02 |
| BE1000783A3 (fr) | 1989-04-04 |
| FR2613226B1 (fr) | 1989-09-15 |
| LU87176A1 (fr) | 1988-11-17 |
| FR2613226A1 (fr) | 1988-10-07 |
| ES2011831A6 (es) | 1990-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004072091A1 (ja) | 糖脂質誘導体及びその製造法並びにそれらの合成中間体及びその製造法 | |
| CA1315793C (en) | Method for controlling emesis caused by chemotherapeutic agents and antiemetic carboxamides useful therein | |
| JPS63107972A (ja) | ２−フェニルベンズオキセピン誘導体及び該誘導体を含有する医薬 | |
| IL30782A (en) | Amino guanidines | |
| US3860636A (en) | Substituted indenyl phosphonic acids having anti-inflammatory activity | |
| JPH07502487A (ja) | 血糖低下性チアゾリジンジオンとその中間体 | |
| Soliman et al. | Preparation and antidiabetic activity of new 3‐methyl‐5‐phenylpyrazolesulfonylurea derivatives | |
| EP0350878A2 (en) | Conjugated gamma-oxybutenolide compounds for treating ulcer | |
| JPS63277672A (ja) | 置換された１，３‐ジオキソランおよび１，３‐ジオキサン誘導体、その製法と使用 | |
| US3923994A (en) | Anti-arthritic compositions comprising a 3-aryl 2-thiohydantoin and methods of producing anti-arthritic acitvity | |
| US3853994A (en) | Diphenyl(3-di alkylaminopropyl)silanes as therapeutics | |
| US3920691A (en) | 5-(3-substituted amino-2-hydroxypropoxy)-1,3-disubstituted pyrazoles and method of preparation | |
| EP0038298B1 (en) | Isoxazolyl indolamines | |
| US4179442A (en) | 4-(Alpha-hydroxy-isopropyl)-5-phenyl-oxazolidin-2-one | |
| US4269838A (en) | Carbamyl piperazine derivatives | |
| EP0253370B1 (en) | 1,3,5-Trithian derivatives | |
| RU2136656C1 (ru) | Производные 4-циано-4-фенилзамещенных циклогексанов или циклогексенов, фармацевтическая композиция (варианты), способ ингибирования фосфодиэстеразы и фактора некроза опухоли | |
| US3949074A (en) | Cardiotonic pharmaceutical compositions containing a cardiac glycoside and method of use | |
| JPH0363224A (ja) | プロトカテキュアルデヒド類の糖誘導体 | |
| US3953600A (en) | Citronellyl benzimidazoles | |
| US4344964A (en) | 1-(Alkanoylamino-aryloxy)-2-hydroxy-3-(alkinyl-amino)-propanes and salts thereof | |
| JPS5936696A (ja) | ２′―デオキシ―５―置換ウリジン誘導体及びそれを含有する抗腫瘍剤 | |
| DE3205457A1 (de) | Oxazolidin-2-one | |
| US3780175A (en) | Silylmethyl thiopseudourea salts | |
| EP1043994A1 (en) | Method for treating multiple sclerosis |